Gout Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Type (NSAIDs, Colchicine, Urate-lowering Drugs, Biologics), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region, By Competition 2020-2030F

Market Overview

The Global Gout Therapeutics Market, valued at USD 2.16 Billion in 2024, is projected to experience a CAGR of 8.80% to reach USD 3.58 Billion by 2030. Gout therapeutics comprise pharmaceutical interventions explicitly designed to manage the acute and chronic manifestations of gout, an inflammatory arthritic condition characterized by the deposition of monosodium urate crystals within joints. These treatments primarily aim to reduce serum uric acid levels and mitigate inflammatory responses. The market's expansion is significantly driven by the escalating global prevalence of gout, exacerbated by an aging population and the increasing incidence of associated metabolic comorbidities, such as obesity and hypertension. Additionally, the ongoing development and introduction of novel, targeted therapies contribute to market momentum by offering improved patient outcomes. According to the American College of Rheumatology, approximately 9.2 million adults in the United States were affected by gout as of 2025.

However, a notable challenge impeding market growth is the high cost associated with advanced therapeutic options. This, combined with restrictive reimbursement policies, particularly in developing economies, can limit patient access to innovative and effective treatments, thereby affecting overall market penetration.

Key Market Drivers

The escalating global prevalence of gout represents a primary catalyst for market expansion in gout therapeutics. This inflammatory condition, driven by various factors including an aging population and lifestyle changes, continues to affect a substantial portion of the worldwide populace. According to a study published in *The Lancet Rheumatology*, in July 2024, 55.8 million people globally had gout in 2020, with projections indicating a significant increase over the coming decades. This rising patient demographic directly translates into an increased demand for effective diagnostic tools and a broad spectrum of treatment modalities, ranging from acute flare management to long-term urate-lowering therapies, placing considerable pressure on healthcare systems to provide comprehensive care.

Concurrently, advancements in gout treatment and the introduction of novel therapies are profoundly influencing market dynamics by offering improved outcomes and expanding therapeutic options. An enhanced understanding of gout pathophysiology has led to the development of more targeted interventions. Recent years have seen considerable investment in discovering and developing these innovative treatments; for instance, according to the Alliance for Gout Awareness, in the last few years, over $97 million has been invested in 213 research projects aimed at managing chronic gout. This commitment supports pipeline candidates, including new uricase-based therapies and selective urate reabsorption inhibitors, addressing unmet needs in patients with refractory disease. These therapeutic innovations not only improve patient quality of life but also drive market growth, especially considering the significant economic burden. According to a microsimulation study published in *Rheumatology Therapy*, in June 2024, the annual direct and indirect costs of gout in patients with chronic kidney disease in the United States were $38.9 billion in 2023, underscoring the financial impact effective treatments aim to mitigate.

Download Free Sample Report

Key Market Challenges

A significant challenging factor impeding the growth of the Global Gout Therapeutics Market is the high cost associated with advanced therapeutic options, coupled with restrictive reimbursement policies. These financial barriers directly limit patient access to innovative and effective treatments, especially in regions with developing economies. When patients cannot afford or access necessary medications due to prohibitive pricing or insufficient insurance coverage, market penetration for these therapies is severely curtailed.

Restrictive reimbursement policies further exacerbate this challenge, impacting healthcare providers' ability to prescribe preferred high-cost treatments. According to The Rheumatologist, the 2025 conversion factor for Medicare physician payment is set at $32.3465, representing a reduction of more than 2.83% from 2024. This decreasing trend in reimbursement directly affects the financial viability for providers to offer a full spectrum of gout therapeutics, including advanced options. Such policies create an environment where cost-effectiveness often takes precedence over optimal patient outcomes, thereby constraining the overall expansion and adoption of the latest gout treatment advancements.

Key Market Trends

The Global Gout Therapeutics Market is currently experiencing a significant shift towards more specialized and advanced treatment modalities. This includes a notable trend in the increasing focus on targeted biologic therapies, which offer more precise mechanisms of action compared to conventional treatments. These therapies aim to address specific pathways involved in gout pathogenesis, particularly for patients who do not respond adequately to traditional urate-lowering agents. According to MedCity News, on July 19, 2024, GRO Biosciences raised $60 million in Series B financing to advance its engineered protein technology for gout, aiming to overcome immune response limitations of existing biologic treatments. This investment underscores the industry's commitment to developing innovative solutions that can offer improved efficacy and tolerability, ultimately expanding therapeutic options for complex cases of gout.

Another pivotal trend influencing the market is the increased integration of digital health and telemedicine solutions. These technologies are transforming how gout care is delivered, enhancing patient access, monitoring, and adherence to treatment regimens. Telemedicine appointments and digital platforms facilitate remote consultations, medication management, and lifestyle advice, which are crucial for a chronic condition like gout. According to a report by the American Medical Association, on January 5, 2024, nearly three-quarters (74.4 percent) of physicians had implemented telehealth programs in their practice by 2022, representing a substantial increase from 25.1 percent in 2018. This widespread adoption reflects the growing recognition of digital health's role in providing continuous and accessible care, thereby supporting better long-term management of gout.

Segmental Insights

The Urate-lowering Drugs segment is experiencing rapid growth in the Global Gout Therapeutics Market due to its essential role in addressing the root cause of gout: hyperuricemia. These medications, including xanthine oxidase inhibitors and uricosuric agents, work to either reduce uric acid production or enhance its excretion, thereby preventing crystal formation and long-term joint damage. Growing awareness of the need for continuous management in chronic gout, coupled with evolving clinical guidelines from bodies such as the American College of Rheumatology, which advocate for a treat-to-target strategy to achieve sustained serum urate reduction, further fuels segment expansion. This shift towards proactive, long-term disease modification rather than merely symptom relief underpins the increasing adoption of these vital therapeutics.

Regional Insights

North America stands as the leading region in the global gout therapeutics market, driven by several key factors. The region experiences a high prevalence of gout, creating a significant demand for effective treatment options. This demand is met by a robust and advanced healthcare infrastructure that facilitates early diagnosis and provides access to prompt therapeutic interventions. Moreover, substantial investments in research and development by major pharmaceutical companies, coupled with supportive reimbursement policies through private health plans and governmental programs like Medicare, enhance patient access to innovative and advanced therapies. The strong regulatory framework, notably from the U. S. Food and Drug Administration, also accelerates the introduction and adoption of novel drugs, collectively strengthening North America's dominant market position.

Recent Developments

• In September 2025, Atom Therapeutics Co., Ltd. reported that its global Phase IIb/III clinical trial for lingdolinurad (ABP-671) successfully achieved its primary endpoint. This novel orally administered URAT1 inhibitor demonstrated significant efficacy in reducing serum uric acid levels while maintaining a favorable safety and tolerability profile in patients with chronic gout. These breakthrough research findings represent a notable advancement in developing new oral treatment options for managing chronic gout and hyperuricemia.

• In July 2025, Shanton Pharma announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to its Investigational New Drug, SAP-001. This designation was for the treatment of hyperuricemia in adult patients with gout who are refractory to conventional therapies. The decision by the FDA followed the release of topline data from a Phase IIb study, which highlighted SAP-001's novel first-in-class mechanism of action by targeting a distinct kidney transporter to reduce serum urate levels.

• In June 2025, Changchun Genescience Pharmaceutical received approval in China for Firsekibart (Genakumab), a fully human monoclonal antibody targeting interleukin-1β (IL-1β). This new product launch provides a novel treatment option for gouty arthritis, particularly for patients who exhibit intolerance or an insufficient response to non-steroidal anti-inflammatory drugs (NSAIDs) or colchicine. Firsekibart, functioning as an IL-1β inhibitor, addresses a considerable need for long-acting, targeted anti-inflammatory therapies within the Chinese market, impacting millions of gout patients.

• In July 2024, Sobi initiated the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for SEL-212, an investigational combination therapy for chronic refractory gout. This significant regulatory step followed positive outcomes from the pivotal DISSOLVE I and II clinical studies. SEL-212 aims to lower serum urate levels and reduce harmful urate deposits that can lead to severe gout flares and joint deformities. The FDA had previously granted Fast Track designation to SEL-212 in March 2024, underscoring the pressing need for novel treatments in this debilitating condition.

Key Market Players

• Abbott Laboratories Inc
• Medtronic Plc
• Boston Scientific Corp
• Becton, Dickinson and Company
• Novartis AG
• GlaxoSmithKline plc
• Allergen, Inc.
• W. L. Gore & Associates, Inc.
• Stryker Corporation
• Terumo Corporation

Report Scope:

In this report, the Global Gout Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Gout Therapeutics Market, By Drug Type:

o   NSAIDs

o   Colchicine

o   Urate-lowering Drugs

o   Biologics

• Gout Therapeutics Market, By Distribution Channel:

o   Hospital Pharmacies

o   Retail Pharmacies

o   Online Pharmacies

• Gout Therapeutics Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Gout Therapeutics Market.

Available Customizations:

Global Gout Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Gout Therapeutics Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]